The human adenovirus type 5 ( Ad5 ) early region 1A ( E1A ) proteins have been shown to have potent antitumor effects, due to their ability to reprogram oncogenic signalling pathways in tumor cells. The success of E1A antitumor therapy in animal models has led to its use in phase I and phase II clinical trials, where liposome -based delivery vehicles are being used to deliver a plasmid encoding E1A. To increase the efficiency of E1A delivery to tumors, we have developed an Ad vector deleted of all viral protein coding sequences ( termed helper -dependent Ad vectors, hdAds ) with the exception of E1A, designated hdAd -E1A. In culture, this vector mediated high -level expression of E1A gene products. A549 cells, a human lung adenocarcinoma cell line, infected with hdAd -E1A showed a reduced proliferative capacity in adherent culture, and the ability to form colonies in soft agarose was completely abolished. In contrast, A549 infected with an hdAd expressing -gal were able to form colonies of a similar size and frequency as uninfected cells. Under serum -depleted conditions, expression of E1A within A549 led to the induction of apoptosis. Finally, A549 cells treated with hdAd -E1A showed approximately 10 -fold greater sensitivity to the chemotherapeutic drug cisplatin. Taken together, these data indicate that the use of hdAd provides a simple and effective method to deliver E1A to cancer cells, and results in reduction in the tumorigenic potential of the cells, as well as increasing the cells sensitivity to anticancer drugs.
T he adenovirus ( Ad ) early region 1 ( E1 ) is the first region transcribed from the viral genome after infection of a cell ( reviewed in 1 ) . Two groups of transcripts are produced from this region, E1A and E1B that, together, encode proteins that function to modulate the cellular environment to enhance the ability of the virus to replicate. E1B proteins primarily function to inhibit p53, thereby preventing p53 -mediated cell death.
2,3 Ad5 E1A produces two major transcripts, 12S and 13S, giving rise to polypeptides of 243 and 289 amino acids, respectively. The primary function of E1A is to activate viral transcription and to reprogram cellular gene expression, which is accomplished through the ability of E1A proteins to interact with a variety of different cellular transcription factors and regulatory proteins, including p300 / CBP, P /CAF, CtBP, and the pocket proteins RB, p107, and p130. 4 -10 Through these diverse interactions, E1A can activate or repress transcription, induce entry and passage through the cell cycle, and block differentiation. 11 Considering the natural function of E1A in promoting cell cycle progression, it seems somewhat paradoxical that E1A, when delivered alone, has been reported to have such a strong anticancer effect ( reviewed in Ref. [12 ] ). However, the fundamental and profound changes that E1A induces within the cell, in the absence of other viral gene products (most notably E1B ), leave the cell in a fragile state highly susceptible to cell death by a variety of mechanisms.
E1A is able to exert its anticancer effect on many different tumor types arising through diverse mechanisms. 13 One popular hypothesis is that E1A acts to ''reversetransform'' tumors by overriding most oncogenic signaling pathways to yield nontumorigenic cells.
12 E1A -mediated effects include reestablishment of contact-inhibited cell growth, inhibition of metastasis by repressing a variety of proteases, sensitizing cells to chemotherapeutic drugs, TNF -, ionizing radiation, and anoikis. 12,14 -23 Moreover, it has been shown that inhibition of angiogenesis and induction of apoptosis are involved in an E1A -mediated bystander effect resulting in tumor suppression. 24 Due to the wide -ranging effects of E1A and the promising preclinical data, seven Phase I or Phase II human clinical trials have been initiated or completed involving E1A delivery to ovarian, breast, or head and neck tumors. 25 However, a Phase I trial of intratumoral liposome -E1A delivery to 16 patients with recurrent breast or head and neck cancer demonstrated that, although the treatment was well tolerated, only 2 patients had a minor response, 8 showed disease stabilization, and 6 had progressive disease. 26 The low response rate may reflect the inefficiency of the lipid -based delivery system that typically gives rise to sparse protein expression that persists for only a short time.
Previously, we described a class of Ad -based vector that is deleted of all viral protein coding sequences, termed helper -dependent Ad vectors ( hdAds ). 27 hdAds can transduce cells with an efficiency identical to E1 -deleted Ad vectors, but are not associated with the acute and chronic toxicity or inflammation frequently associated with E1 -deleted Ad. 28 -30 The development of this vector system provided a unique opportunity to exploit the high efficiency with which Ad infects cells to deliver E1A in the absence of all other viral gene products, and evaluate the vector's effectiveness as an anticancer therapeutic. Here we show that delivery of hdAd -E1A to the A549 tumor line results in a reduction in their proliferation rate, enhanced cell death, increased sensitivity to cisplatin, and abolishes their ability to form colonies in soft agar. Taken together, these results indicate that E1A is able to reduce the tumorigenic capacity of these cells.
Materials and methods

Cell and virus culture
All cell culture media and reagents were obtained from Gibco Laboratories (Grand Island, NY ) . 293 31 and A549 ( human lung carcinoma, ATCC CCL 185 ) cells were grown in monolayer in minimum essential medium supplemented with 100 U of penicillin / mL, 100 mg of streptomycin / mL, 2.5 mg fungizone/mL, and 10% fetal bovine serum ( complete medium ). Recombinant Ad helper viruses were grown and titered on 293 cells, as previously described. 32 The 293 -derived cell line that stably expresses the Cre recombinase, 293Cre4, 33 was propagated in complete medium supplemented with 0.4 mg /mL G418.
Helper-dependent Ad vectors were propagated and titered as previously described. 27 Both hdAd -lacZ and hdAd -E1A have a similar Ad backbone structure. These vectors are hdAds deleted of all Ad protein coding sequences, but containing an Ad5 right and left inverted terminal repeats and packaging signal. To maintain the size of the vectors above the limit for efficient DNA packaging ( $28 kb ), 34 both hdAd -lacZ and hdAd -E1A contain a $22 -kb fragment of eukaryotic DNA derived from the human hypoxanthineguanine phosphoribosyltransferase (HPRT ) gene, as described elsewhere. 35 HdAd -lacZ contains the E. coligalactosidase gene under the regulation of the murine cytomegalovirus immediate -early promoter ( MCMV ) and Simian virus 40 polyadenylation (pA ) sequence (Fig 1A ) . hdAd -E1A contains an identical -gal expression cassette but, in addition, encodes E1A in its native position and under the regulation of its native promoter. The helper virus, AdLC8cluc, 27 was present at a concentration of 1.9Â10 6 pfu /mL in our stocks of hdAd -E1A (1.6Â10 10 E1A -transducing particles /mL ) giving rise to a helper contamination of approximately 0.01%. Our hdAd -lacZ stocks contained a helper virus contamination of $0.01% (2.6Â10 10 LacZ -transducing particles /mL and 2.5Â10 6 pfu /mL helper virus ). 
Western blot analysis
Growth of adherent cells
Cell growth assays were performed using a quantitative crystal violet staining method. Cells were infected at MOI= 100 for 1 hour, and allowed to recover for one additional hour. The cells were then trypsinized, and replated at 2Â10 4 cells per 35 -mm dish. At each time point, duplicate dishes were fixed ( 0.2% glutaraldehyde, 2% paraformaldehyde, 2 mM MgCl 2 in phosphate -buffered saline ) for 10 minutes and stained with 0.1% crystal violet solution for 30 minutes. The stained monolayers were then washed extensively with distilled water, inverted, and allowed to dry overnight. At the end of the assay, the stained monolayers were overlayed with 1 mL of 10% acetic acid, incubated with gentle shaking for 5 minutes at room temperature, and the liquid removed to a fresh microfuge tube. The amount of crystal violet in solution was then determined spectrophotometrically (O.D. 595 nm ) and compared to a serial dilution standard of crystal violet to ensure the readings were within the linear response range. Cisplatin (Faulding, Montreal, Quebec, Canada ) was obtained at a concentration of 1 mg / mL, in a stabilizing solution containing mannitol ( 1 mg /mL ) and sodium chloride (9 mg /mL ), and was a kind gift of Julie LeBlanc (Ottawa Regional Cancer Centre, Ottawa, ON ). For cisplatin -mediated cell killing, the cells were infected as described above, except the medium was supplemented with varying concentrations of cisplatin immediately after replating, and the cells were stained with crystal violet 4 days later. To evaluate the effect of MOI on cell viability, approximately 80% confluent monolayers were infected with varying MOI, and overlayed with complete medium containing cisplatin. Seven days later, the monolayers were stained with crystal violet as described above.
Soft -agarose colony formation assays
The tumorigenic potential of the cells was evaluated based on their ability to form colonies in soft agarose. Briefly, cells were infected in 60 -mm dishes at an MOI of 100 for 1 hour, and allowed to recover for one additional hour. The cells were then trypsinized, and mixed at 2Â10 5 or 2Â10 4 cells ( in 1 mL of complete medium ) with 3 mL of medium supplemented with 0.5% agarose. The entire 4 mL was then overlayed on a bottom layer of agarose, which consisted of complete media supplemented with 0.5% agarose, in sixwell plates. The plates were incubated from 7 to 20 days, and colonies were visualized using an inverted microscope ( Leitz, Toronto, CN ) and images were captured with a charged coupled device ( CCD ) camera (Axiocam, Zeiss, Toronto, CN ).
Immunocytochemistry and apoptosis detection
The expression and effect of E1A on cell survival of A549 cells was measured using immunofluorescence. A549 cells (5Â10 5 cells per 35-mm plate ) were infected at an MOI= 10 for 1 hour with either hdAd -lacZ or hdAd -E1A or uninfected ( control ). Each dish contained three glass coverslips that were used for subsequent immunofluorescent detection assays. Following infection, the viral solution was replaced with medium supplemented with 0.1% serum and the cells were incubated at 378C. After specific time intervals ( 24 and 48 hours ), coverslips were removed from each dish and the cells were fixed in 3.7% formaldehyde for 10 minutes and permeabilized in 0.5% Triton X -100 for 10 minutes at room temperature. Apoptosis detection was performed using the TdT terminal deoxynucleotidyl transferase -mediated dUTP nick end labeling ( TUNEL ) ApopTag Red in situ apoptosis detection kit ( Intergen, Purchase, The stuffer DNA is a 22 -kb fragment of the human hypoxanthine -guanine phosphoribosyltransferase ( HPRT ) gene. HdAd -E1A is identical to HdAd -lacZ but contains the entire Ad5 E1A coding sequence. Ad5 inverted terminal repeats ( black arrows ) and packaging signal ( É ) are also shown. B: Western blot analysis of E1A proteins produced from hdAd -E1A in A549 cells.
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Results
Expression of E1A
Our E1A expression vector contains the entire E1A coding sequence under the regulation of its endogenous promoter, and located in its normal position in the Ad genome ( Fig 1A ) . To assess expression from this vector, we infected A549 at an MOI of 10 and, 24 hours later, prepared protein samples for Western blot analysis. As shown in Figure 1B infected with hdAd -lacZ. Thus, hdAd -E1A is able to effectively transduce A549 and result in the production of multiple species of E1A proteins.
Proliferation of adherent cells infected with hdAd
E1A is reported to have a strong effect on the tumorigenic potential of cancer cells (i.e., ability to grow in soft agar or form solid tumors in mice), but only marginally influences the proliferative rate of adherent cells in growth medium ( i.e., 10% FCS ). 36 To investigate this phenomenon with our hdAd vector, we infected A549 cells with hdAd -E1A or hdAd -lacZ at an MOI of 100, and compared growth of the cells in medium supplemented with 10% FCS over a 4 day time course versus uninfected cells (Fig 2) . Based on the slopes of the various curves, the growth rate of hdAd -lacZ and -E1A treated cells was reduced to approximately 81% and 54% of untreated cultures, respectively. The reduced rate of growth does not reflect increased apoptosis in cells infected with hdAd -E1A, because we have not observed increased cell death in these cultures, as assessed by Annexin V labeling at 18 or 24 hours postinfection (data not shown). We also examined adherent colony size after 4 days in culture. All of the treatments resulted in approximately the same number of colonies per dish ( 95 ±11, 98± 11, and 103± 8 colonies per dish for uninfected, hdAd -lacZ and hdAd -E1A, respectively; initial plating of 100 cells per dish ); however, the number of cells per colony was significantly reduced for cells treated with hdAd -E1A. hdAd -E1A treatment resulted in a 27% reduction in the number of cells per colony (53 ± 22 vs. 39± 17 cells per colony for control and hdAd -E1A -treated cells, respectively, P <.01 ), whereas treatment with hdAdlacZ resulted in only a 5% reduction in cell number per Figure 2 Proliferation of adherent cells infected with hdAd. A549 cells were infected with an MOI of 100 with hdAd -lacZ, hdAd -E1A, or mock infected and, at 1 -day intervals, the cells were fixed and stained with crystal violet. The crystal violet was resolubilized in 10% acetic acid, and assayed spectrophotometrically for color intensity.
E1A -induced apoptosis in cells grown in low serum
Although E1A does not induce apoptosis of tumor cells under growth conditions, apoptosis is observed if the cells are stressed by lowering the concentration of growthfactors. 36 We infected cells with hdAd -lacZ or E1A in medium containing 0.1% FCS, and examined expression of E1A by immunocytochemistry and apoptosis by TUNEL ( Fig 3 ) . As expected, no E1A immunoreactivity was observed in uninfected or hdAd -lacZ infected cells at 24 hours (Fig 3A and B ) or 48 hours ( data not shown); however, most cells infected with hdAd -E1A contained ample E1A immunoreactivity within the nucleus ( Fig 3C ) . At 24 hours postinfection, less than 1% of control or hdAdlacZ -treated cells showed TUNEL staining ( Fig 3D and E ) , and this percentage did not increase at 48 hours (Fig 3G and  H ) . Although a similar number of hdAd -E1A -treated cells showed intense TUNEL staining at 24 hours (Fig 3F ) relative to controls, the number of apoptotic cells increased dramatically by 48 hours ( Fig 3I ) . Thus, under serumdepleted conditions, delivery of E1A to A549 cells results in significant cell death by apoptosis.
One possible explanation of our results is that hdAd -E1A is providing functions ( E1A ) that complement the growth of our E1 -deleted helper virus, which is present at low levels in our hdAd stocks. 27 The result would be analogous to infecting the cells with an E1B -deleted Ad vector, which has been shown in many cases to allow selective replication and killing of tumor cells. 37, 38 Complementation between the two viral species would result in very high levels of our E1 - Cancer Gene Therapy E1A -mediated cancer therapy AV Hubberstey et al deleted helper virus in cell supernatants collected from hdAd -E1A -infected cells. A549 cells in 35 -mm dishes were infected at MOI of 100 (relative to the hdAd titer ) with hdAd -lacZ or -E1A and, 7 days later, the supernatant and cell debris was collected and titered on 293 cells. We did not observe any plaque -forming units arising from hdAd -E1A -or hdAd -lacZ -infected cells ( < 1 helper virus per 100 l of supernatant ). Therefore, cell death in our system is not due to complementation and growth of the helper virus.
Synergistic effects of E1A and cisplatin
E1A, by itself, does not result in increased death of A549 cells under growth conditions in vitro. However, treatment of cells with E1A is reported to increase the cells susceptibility to chemotherapeutic drugs. 16, 18, 22 We infected A549 cells with hdAd -lacZ or -E1A ( MOI = 100 ), and then treated the cells with varying concentrations of the chemotherapeutic drug cisplatin. The relative number of cells was determined 4 days later by crystal violet staining ( Fig 4) . We observed complete cell death of uninfected cells or cells treated with hdAd -lacZ at a concentration of 10 g/ mL cisplatin; however, death of hdAd -E1A -treated cells was observed at a 10-fold lower dose of cisplatin ( 1 g/ mL ). Therefore, pretreatment of cells with hdAd -E1A increases their sensitivity to the chemotherapeutic drug cisplatin.
E1A has been shown to mediate bystander effect in that cells treated with E1A appear to release a soluble factor( s ) that is taken up by adjacent, nontransduced cells, resulting in a spread of the E1A effect to cells not initially transduced. 24 This effect is important because it suggests that not all cells of a tumor need to be transduced with the E1A -expressing vector to get a beneficial effect. We therefore examined the relationship between MOI and cell killing, asking the question: what percentage of the cells needs to be transduced with hdAd -E1A to achieve cell death of the entire population of cells. We determined this effect in combination with cisplatin treatment because it provides a clear read -out: all cells treated with E1A die at a concentration of 1 g /mL. Cells were infected at an MOI of 0.3, 1, 3, or 30 with hdAdlacZ or -E1A, or uninfected, overlayed with medium containing 1 g /mL cisplatin, then stained with crystal violet 7 days later. Whereas treatment of A549 with hdAdlacZ had no effect on cell viability compared to uninfected cells, we observed a direct relationship between the number of cells transduced with hdAd -E1A and cell death ( Fig 5) . Figure 4 Effect of cisplatin on hdAd -E1A -infected cells. A549 cells were infected with MOI of 100 of hdAd -lacZ, hdAd -E1A, or uninfected and subjected to varying concentrations of cisplatin. The relative cell survival was determined using a crystal violet staining method, as described in Materials and methods.
Cancer Gene Therapy E1A -mediated cancer therapy AV Hubberstey et al were transduced with the vector (as determined by X -gal staining ), and we observed a 12% reduction in cell viability relative to our hdAd -lacZ -infected control. At an MOI of 1, approximately 13% of the cells were transduced, and we observed an 18% reduction in cell viability. Similar results were observed in mixing experiments where one population of cells was infected at MOI of 100 with hdAd -E1A and then mixed at varying ratios with uninfected cells: no synergistic killing was observed (data not shown ). We conclude that, at least in A549 cells treated with hdAd -E1A, there is no significant bystander effect, even after 1 week, and E1A effects are only observed in cells transduced with the vector.
A549 soft agarose colony formation
To assess whether hdAd -E1A could reduce the tumorigenic potential of cancer cells, we examined the ability of infected cells to form colonies in soft agarose. Cells were infected at an MOI of 100, trypsinized, and replated in soft agarose in 35 -mm dishes and, 20 days later, the plates were examined for colony growth. As shown in Figure 6 , treatment of A549 cells with hdAd -lacZ did not affect their ability to form colonies, and the mean colony size was approximately equivalent to that observed for uninfected cells. In contrast, infection of cells with hdAd -E1A abolished their ability to form colonies. Because the ability to form colonies in soft agarose is generally regarded as a measure of their tumorigenic potential, our data indicates that treatment of cells with hdAd -E1A results in a dramatic reduction in the tumorigenic potential of A549 cells.
Discussion
Ad E1A has been shown to possess strong antitumor activity. Most of these studies have involved cell lines that stably express E1A or liposome -mediated delivery of a plasmid encoding E1A. We reasoned that an Ad vector encoding solely E1A might be a more efficient means to deliver E1A to tumor cells. The development of hdAd vectors that are deleted of all viral protein coding sequences provides a unique opportunity to use a high -efficiency deliver system to deliver E1A to tumor cells. E1A -expressing tumor cells demonstrated enhanced cell death under low serum conditions or in the presence of cisplatin. Indeed, we observed that treatment of cells with E1A resulted in a 10-fold greater sensitivity to the chemotherapeutic drug cisplatin. The mode of action of cisplatin is to form mainly intrastrand DNA cross -links between neighboring purine residues, resulting in termination of DNA synthesis, and induction of DNA repair or even apoptosis, possibly facilitated by p53. 39 In some studies, E1A has been shown to stabilize p53 within the cell leading to its accumulation, 40, 41 although it is evident that E1A can sensitize cells to DNA -damaging agents irrespective of their p53 status. 40, 42 Although A549 are positive for p53, they lack functional p14 ARF , which mediates p53 accumulation by E1A, 43 suggesting that E1A -induced apoptosis in our model is most likely independent of p53 induction. The ability of E1A to confer enhanced sensitivity to radiation -and TNFinduced apoptosis has been attributed, at least in part, to its ability to inhibit the functioning of nuclear factor B (NF-B). 17, 19 NF -B has been demonstrated to have an antiapoptotic effect, blocking apoptosis induced by TNF -, ionizing radiation, and some chemotherapeutic drugs. 44 -47 If the decision of a cell to undergo apoptosis is due to the relative levels of pro -versus antiapoptotic signals, the enhanced death of cisplatin -treated A549 cells when coadministered E1A may reflect an increase in proapoptotic signals (DNA damage and p53 accumulation ) combined with a decrease in antiapoptotic signals (inhibited NF -B function ). Regardless of the mechanism, E1A treatment leads to enhanced sensitivity to cisplatin and other chemotherapeutic drugs, suggesting that, using a combination therapy approach, reduced levels of drug could be administered to patients.
Although E1A has been reported to mediate a strong bystander effect, we did not observe this in experiments using MOIs where only a fraction of the monolayer was infected with hdAd -E1A or in mixing experiments where uninfected cells were combined with infected cells. This suggests that soluble factors were not transported from infected cells to uninfected cells, and strongly suggests that, in our model system, E1A must be expressed within the cell to see an effect. Alternatively, we may be producing insufficient levels of E1A to achieve the bystander effect. We used the native E1A promoter to direct expression, and it has been demonstrated that E1A protein can down -regulate expression from this promoter. 48 If the level of E1A expression does influence the efficacy of the bystander effect, our results may partially explain data from preclinical and clinical trials, where only transient or incomplete effects on tumor growth have been observed. 26, 49 Helper-dependent Ad vectors retain many of the advantages of E1 -deleted, first -generation Ads, mainly the high transduction efficiency of many different cell and tissue types, while having the added advantage of reduced acute and chronic toxicity and increased cloning capacity ($36 kb). This latter point has two obvious advantages. First, anticancer hdAd vectors can be designed with large regulatory regions to achieve tissue -specific gene expression, 50 -52 or incorporation of regulatory systems that allow for gene expression to be turned on or off. 51, 53 Secondly, hdAd vectors could be used to simultaneously deliver multiple therapeutic genes to tumors. For example, delivery of E1A and wild -type p53 to p53-null tumors might be Uninfected hdAd-lacZ hdAd-E1A Figure 6 Inhibition of colony formation in soft agarose for cells infected with hdAd -E1A. A549 cells were infected at an MOI of 100 with hdAd -lacZ, hdAd -E1A, or uninfected and replated in soft agarose. Twenty days later, the cultures were inspected for colony formation. Representative fields of view are shown.
Cancer Gene Therapy E1A -mediated cancer therapy AV Hubberstey et al expected to increase their sensitivity to chemotherapy. The versatility of the hdAd system should provide an effective platform to design novel cancer gene therapy strategies.
